Abstract

BackgroundBiological therapies optimization in joint inflammatory diseases is indicated in patients who have more than six months in clinical remission. The main objective is to limit the occurrence of adverse...

Full Text

Published Version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
THU0183 Optimization of Biological Treatment in Patients with Rheumatoid Arthritis and Polyarticular Psoriatic Arthritis. A 6-Month Results
M.J Rodriguez Valls ... J.J Perez Venegas
Annals of the Rheumatic Diseases | VOL. 73
M.J Rodriguez Valls, et. al.M.J Rodriguez Valls ... J.J Perez Venegas
01 Jun 2014
FRI0265 Immunogenicity of Anti-TNF Antagonists in Patients with Rheumatoid Arthritis or Polyarticular Psoriatic Arthritis in Clinical Remission or Low Disease Activity: The Inmunoremar Study
R Sanmarti ... A Gonzalez Navarro
Annals of the Rheumatic Diseases | VOL. 73
R Sanmarti, et. al.R Sanmarti ... A Gonzalez Navarro
01 Jun 2014
FRI0093 Immunogenicity of TNF Inhibitors in Patients with Rheumatoid Arthritis or Polyarticular Psoriatic Arthritis in Clinical Remission or Low Disease Activity: A One-Year Multicentre Prospective Study (The Inmunoremar Study)
R Sanmarti ... M García-Manrique
Annals of the Rheumatic Diseases | VOL. 75
R Sanmarti, et. al.R Sanmarti ... M García-Manrique
01 Jun 2016
AB1046 Could serum tweak level be an indicator of subclinical atherosclerosis in rheumatoid arthritis?
M Ucer ... S Yavuz
Annals of the Rheumatic Diseases | VOL. 76
M Ucer, et. al.M Ucer ... S Yavuz
01 Jun 2017
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.